Hala M Hatab1, Fatma F Abdel Hamid1, Ahmed F Soliman1, Tamer A Al-Shafie2, Yahia M Ismail3, Motawa E El-Houseini4. 1. Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt. 2. Pharmacology and Therapeutics Department, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt. 3. Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt. 4. Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Abstract
BACKGROUND: Investigating and evaluating possible alternative therapeutic strategies to control hepatocellular carcinoma (HCC) is a critical need because of its high prevalence and being one of the most lethal cancers. Curcumin and taurine showed potent anti-tumor activities in pre-clinical and clinical studies by targeting multiple pathways. Thus, this study was designed to assess the effect of a combined treatment consisted of curcumin, piperine, and taurine on circulating levels of interleukin-10 (IL-10), and microRNAs miR-141 and miR-21. METHODS: Twenty eligible HCC patients administrated an oral dose of 4 g curcumin, 40 mg piperine, and 500 mg taurine daily for three successive treatment cycles, each was a 30-day. The level of IL-10 along with the expression levels of miR-141, and miR-21 were monitored in serum before starting the treatment and after each cycle. Patients were followed-up for a period of 24 months. RESULTS: The combined treatment was able to produce a significant decrease in the levels of serum IL-10, and miR-21 while it resulted in a non-significant up-regulation of serum miR-141 expression level. At the end of the follow-up period, the median overall survival (OS) rate was found to be 17.00 months with a worse OS in patients with high baseline levels of circulating IL-10 and miR-21 compared to those with low levels. In contrast, a low baseline level of circulating miR-141 was associated with poor prognosis. CONCLUSIONS: The combined treatment may be able to increase the OS rate by altering the circulating level of IL-10 and miR-21.
BACKGROUND: Investigating and evaluating possible alternative therapeutic strategies to control hepatocellular carcinoma (HCC) is a critical need because of its high prevalence and being one of the most lethal cancers. Curcumin and taurine showed potent anti-tumor activities in pre-clinical and clinical studies by targeting multiple pathways. Thus, this study was designed to assess the effect of a combined treatment consisted of curcumin, piperine, and taurine on circulating levels of interleukin-10 (IL-10), and microRNAs miR-141 and miR-21. METHODS: Twenty eligible HCC patients administrated an oral dose of 4 g curcumin, 40 mg piperine, and 500 mg taurine daily for three successive treatment cycles, each was a 30-day. The level of IL-10 along with the expression levels of miR-141, and miR-21 were monitored in serum before starting the treatment and after each cycle. Patients were followed-up for a period of 24 months. RESULTS: The combined treatment was able to produce a significant decrease in the levels of serum IL-10, and miR-21 while it resulted in a non-significant up-regulation of serum miR-141 expression level. At the end of the follow-up period, the median overall survival (OS) rate was found to be 17.00 months with a worse OS in patients with high baseline levels of circulating IL-10 and miR-21 compared to those with low levels. In contrast, a low baseline level of circulating miR-141 was associated with poor prognosis. CONCLUSIONS: The combined treatment may be able to increase the OS rate by altering the circulating level of IL-10 and miR-21.
Authors: A L Cheng; C H Hsu; J K Lin; M M Hsu; Y F Ho; T S Shen; J Y Ko; J T Lin; B R Lin; W Ming-Shiang; H S Yu; S H Jee; G S Chen; T M Chen; C A Chen; M K Lai; Y S Pu; M H Pan; Y J Wang; C C Tsai; C Y Hsieh Journal: Anticancer Res Date: 2001 Jul-Aug Impact factor: 2.480
Authors: G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi Journal: Ann Surg Date: 2000-04 Impact factor: 12.969
Authors: Susanne Beckebaum; Xia Zhang; Xiao Chen; Zhengya Yu; Andrea Frilling; Grzegorz Dworacki; Hans Grosse-Wilde; Christoph Erich Broelsch; Guido Gerken; Vito R Cicinnati Journal: Clin Cancer Res Date: 2004-11-01 Impact factor: 12.531
Authors: Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie Journal: Oncogene Date: 2003-01-23 Impact factor: 9.867
Authors: Patrycja Koszałka; Grzegorz Stasiłojć; Natalia Miękus-Purwin; Maciej Niedźwiecki; Maciej Purwin; Szymon Grabowski; Tomasz Bączek Journal: Int J Mol Sci Date: 2022-04-26 Impact factor: 6.208